B.H. reports fees from Janssen-Cilag (for advisory boards, educational grants, consultations, investigator initiative studies), AbbVie (for advisory boards, educational grants, consultations, investigator initiative studies), Novartis Pharma (for advisory boards, consultations, investigator initiative studies), UCB Pharma (for advisory boards, consultations), Leo Pharma (for consultations), Solenne B.V. (for investigator initiative studies), Celgene (for consultations and investigator initiative studies), Akari Therapeutics (for consultations and investigator initiative studies), Philips (for consultation), Roche (for consultation), Regeneron (for consultation) and Sanofi (for consultation); the fees were payed to the institution. E.P.P. has received honoraria from AbbVie, Amgen, Celgene, Janssen, Galderma, Novartis and Pfizer for participation as a speaker and for serving on advisory boards; E.P.P. also received investigator-initiated grants (paid to Erasmus MC) from AbbVie, AstraZeneca, Janssen and Pfizer.